{
    "2020-10-19": [
        [
            {
                "time": "2023-11-07",
                "original_text": "高瓴再出手！8亿亏损能否助力加科思癌症疗法走向新纪元？ 亏损",
                "features": {
                    "keywords": [
                        "高瓴",
                        "癌症疗法",
                        "亏损",
                        "加科思"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-11-07",
                "original_text": "医药生物行业周报：冠脉支架国采方案落地 头部企业有望相对受益",
                "features": {
                    "keywords": [
                        "医药生物",
                        "冠脉支架",
                        "国采",
                        "头部企业"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-07",
                "original_text": "医药生物行业报告：持续看好流感及肺炎相关疫苗销售 关注医药三季报业绩主线",
                "features": {
                    "keywords": [
                        "医药生物",
                        "流感",
                        "肺炎",
                        "疫苗",
                        "三季报"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-07",
                "original_text": "创业板指跌幅扩大至1%，乐普医疗、贝达药业、欧普康视、康龙化成领跌",
                "features": {
                    "keywords": [
                        "创业板指",
                        "乐普医疗",
                        "贝达药业",
                        "欧普康视",
                        "康龙化成"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}